![Virtual Booth](https://www.pharmacompass.com/image/vb/vb-orange-btn.png)
![EuroAPI Header](https://www.pharmacompass.com/image/flap/euroapi-w34-desktop-headergif-72716.gif)
![EuroAPI Header](https://www.pharmacompass.com/image/flap/euroapi-w34-mob-headergif-95876.gif)
20
Krka, D.d., Novo Mesto Novo Mesto Si, based in Slovenia, is a pharmaceutical company that stands out with its certifications from FDA and EDQM.
One of their significant offerings is Lovastatin, supported by a 'Withdrawn by Holder' Certificate of Suitability (CEP) with the number R1-CEP 2004-191 - Rev 01
This Chemical Type CEP, issued on December 02, 2010, remains in force until December 02, 2016, ensuring its reliability within the pharmaceutical industry.
Substance Number 1538 associated with this CEP further emphasizes